rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MCRB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Seres Therapeutics Inc earnings beat by $0.01, revenue fell short of estimates
      Nov 4Investing.comMCRB
      Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceMCRB
      Seres Therapeutics: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceMCRB
      Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
      Nov 4Yahoo FinanceMCRB
      Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
      Nov 3Yahoo FinanceMCRB
      Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
      Oct 15Yahoo FinanceMCRB
      Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Emp

      Sep 8Yahoo FinanceMCRB
      Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences

      Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Type of Product, Route of Administration, Target Indication, Therapeutic Area, End User and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period. Market expansion

      Sep 7Yahoo FinanceMCRB
      Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026. A live webcast of the presentation will be accessible here and will be available for replay on the “Events and Presentations” section of Seres’ website

      Sep 1Yahoo FinanceMCRB

      This is the newest page. Registered accounts read further back.